DrugPatentWatch Database Preview
Drugs in Development Information for Defactinib
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
What is the development status for investigational drug Defactinib?
Defactinib is an investigational drug.
There have been 13 clinical trials for Defactinib.
The most recent clinical trial was a Phase 1 trial, which was initiated on September 1st 2013.
The most common disease conditions in clinical trials are Mesothelioma, Ovarian Neoplasms, and Pancreatic Neoplasms. The leading clinical trial sponsors are Verastem, Inc., Merck Sharp & Dohme Corp., and National Cancer Institute (NCI).
There are four US patents protecting this investigational drug and forty-two international patents.
Summary for Defactinib
| US Patents | 4 |
| International Patents | 42 |
| US Patent Applications | 16 |
| WIPO Patent Applications | 5 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 1 (2013-09-01) |
| Vendors | 46 |
Recent Clinical Trials for Defactinib
| Title | Sponsor | Phase |
|---|---|---|
| Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma | Merck Sharp & Dohme Corp. | Phase 2 |
| Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma | Verastem, Inc. | Phase 2 |
| Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 |
Clinical Trial Summary for Defactinib
Top disease conditions for Defactinib
Top clinical trial sponsors for Defactinib
US Patents for Defactinib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Defactinib | Start Trial | Sulfonyl amide derivatives for the treatment of abnormal cell growth | Pfizer Inc (New York, NY) | Start Trial |
| Defactinib | Start Trial | Sulfonyl amide derivatives for the treatment of abnormal cell growth | Pfizer Inc (New York, NY) | Start Trial |
| Defactinib | Start Trial | Sulfonyl amide derivatives for the treatment of abnormal cell growth | Start Trial | |
| Defactinib | Start Trial | Methods and compositions for treating abnormal cell growth | Verastem, Inc. (Needham, MA) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Defactinib
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Defactinib | Argentina | 066125 | 2027-04-18 | Start Trial |
| Defactinib | Australia | 2008240359 | 2027-04-18 | Start Trial |
| Defactinib | Brazil | PI0810411 | 2027-04-18 | Start Trial |
| Defactinib | Canada | 2684447 | 2027-04-18 | Start Trial |
| Defactinib | Chile | 2008001076 | 2027-04-18 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
